secwatch.observer — SEC 8-K summary
======================================

Issuer:     Bolt Biotherapeutics, Inc. (BOLT)
CIK:        0001641281
Form:       8-K
Filed at:   2022-11-10T23:59:59+00:00
Accession:  0000950170-22-024476
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bolt Biotherapeutics Q3 2022 operating loss $22.3M; cash $209.6M funds through 2025
--------------------------------------------------------------------------------

- Cash $209.6M as of Sep 30, 2022; expected to fund operations and milestones through 2025.
- BDC-1001 dose-escalation trial on track to complete enrollment by year-end; topline data and RP2D expected Q1 2023.
- BDC-3042 IND-enabling progressing; on track for clinical entry in 2023.
- Collaboration revenue $2.1M (up from $0.8M YoY); R&D expense $19.0M, G&A $5.5M.
- Loss from operations $22.3M vs $23.5M in Q3 2021.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1641281/000095017022024476/0000950170-22-024476-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1641281/000095017022024476/bolt-20221110.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-024476

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer